Facebook
Twitter
LinkedIn
ForwardAUA Expert Exchange Podcast: Discussions in Prostate Cancer (2024)
Based on the documented need for additional education in prostate cancer, the AUA has developed AUA Expert Exchange Podcast: Discussions in Prostate Cancer. To address the educational needs of the urologic care team, we recommend the following topic-specific podcasts:
- Biomarkers and Molecular Imaging for Prostate Cancer
- Appropriate Use of Genetic Testing (who, what, when and how?)
- Treatment Intensification in Metastatic HSPC
- Sequencing of Agents
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
Lantheus Medical Imaging
Novartis Pharmaceuticals Corporation
Target Audience
- Urologists
Learning Objectives
At the conclusion of these activities, participants will be able to:
Biomarkers and Molecular Imaging for Prostate Cancer
- Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers.
- Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring.
- Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.
Appropriate Use of Genetic Testing (who, what, when and how?)
- Identify the patient populations that should be considered for genetic testing in prostate cancer, based on family history, personal risk factors, and clinical indications.
- Integrate genetic testing into clinical practice for prostate cancer, including developing workflows, referral processes, and multidisciplinary collaboration.
- Utilize genetic test results to inform personalized treatment plans for prostate cancer patients, including targeted therapies and risk reducing strategies.
Treatment Intensification in Metastatic HSPC
- Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology.
- Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks.
- Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.
Sequencing Of Agents
- Review the latest evidence and clinical guidelines that inform the sequencing of therapeutic agents in metastatic prostate cancer, including data from key clinical trials.
- Implement strategies for managing and overcoming resistance to therapy in metastatic prostate cancer, considering the role of sequencing in delaying resistance.
- Apply best practices for monitoring treatment response and disease progression in patients undergoing therapy, and adjust sequencing strategies based on these observations.
EDUCATION COUNCIL DISCLOSURES
COI REVIEW WORK GROUP DISCLOSURES
COI Review Workgroup Disclosures
AUA Office of Education Staff has nothing to disclose.
Faculty disclosures are located on individual activities. To view faculty disclosures, navigate to the "Take Course/Register" tab and select the activity you wish to view.
All relevant financial relationships have been mitigated.
AUA ACCREDITATION INFORMATION
Method of Participation: Learners will participate in this online educational activity by listening to the podcasts, answering multiple choice questions, examining patient tools and resources and completing the posttests and evaluations. To claim CME credit for these enduring materials, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 2.00 hours
Release Date: September, 2024
Expiration Date: September, 2025
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.
Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification relevant financial relationships that result in of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.